文献速递主动脉疾病

多发性胸主动脉疾病血管内修复术后结局评估研究(SUMMIT)的结果

Results from the Study to Assess Outcomes After Endovascular Repair for Multiple Thoracic Aortic Diseases (SUMMIT).
PubMed 文献 · J Vasc Surg · 2018-05-07

SUMMIT研究汇总了5项Cook赞助的多中心试验中521例胸主动脉腔内修复(TEVAR)患者数据,分析不同主动脉疾病的结局及风险因素。30天死亡率为1.7%,1年全因死亡累积率为8.1%。急性及非急性B型主动脉夹层患者再干预风险显著高于胸主动脉溃疡患者。

要点

  • TEVAR术后30天死亡率为1.7%,围术期卒中3.1%,截瘫1.2%。
  • 1年全因死亡累积率8.1%,再干预累积率6.0%。
  • 急性及非急性B型主动脉夹层再干预风险显著高于胸主动脉溃疡(HR 5.65和6.60)。

核心结论

  • SUMMIT研究显示TEVAR术后30天死亡率和卒中率极低,随访期间主动脉疾病相关死亡率低。
  • B型主动脉夹层与较高的再干预风险相关,可能归因于疾病自然史。
  • 年龄、心肾功能减退、髂动脉入路解剖困难、术中输血及早期神经系统并发症与较高的累积全因死亡风险相关。

研究设计与样本

  • SUMMIT研究为汇总5项Cook赞助的多中心试验数据的事后分析,共纳入521例接受Zenith平台胸主动脉支架的TEVAR患者。
  • 主要结局包括30天和1年死亡率和发病率、累积死亡率和再干预率;采用Cox回归分析死亡和再干预的风险因素。

主要发现

  • 521例患者中男性占67%,平均年龄67.2±15岁;胸主动脉瘤329例,胸主动脉溃疡56例,急性B型主动脉夹层55例,非急性B型主动脉夹层31例,钝性胸主动脉损伤50例。
  • 30天总死亡率为1.7%,围术期卒中3.1%,截瘫1.2%,近端I型内漏0.4%。
  • 1年累积率:全因死亡8.1%,卒中4.0%,截瘫1.2%,近端I型内漏0.8%,二次干预6.0%。
  • 多因素分析显示全因死亡的显著预测因素包括年龄(每增加1岁HR 1.04)、充血性心力衰竭(HR 2.87)、血清肌酐(每1 mg/dL HR 1.19)、髂动脉迂曲(HR 1.32)、输血(每500 mL浓缩红细胞HR 1.59)以及30天卒中(HR 3.93)、截瘫(HR 7.79)或轻截瘫(HR 2.46)的发生。
  • 与胸主动脉溃疡患者(参照组)相比,接受夹层治疗的患者再干预风险显著更高(急性B型主动脉夹层HR 5.65,非急性B型主动脉夹层HR 6.60),而胸主动脉瘤或钝性胸主动脉损伤患者无此显著差异;术中对比剂(每100 mL HR 1.31)和输血量(每500 mL浓缩红细胞HR 1.42)也是再干预的显著预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is currently the treatment of choice for most diseases of the descending thoracic aorta. Using data from the Study to Assess Outcomes After Endovascular Repair for Multiple Thoracic Aortic Diseases (SUMMIT) study we investigated the outcomes of TEVAR for different aortic diseases and risk factors associated with the outcomes. METHODS: The SUMMIT study included aggregated data of 521 TEVAR patients from five Cook-sponsored multicenter trials evaluating thoracic endografts of the Zenith platform (William Cook Europe, ApS, Bjaeverskov, Denmark). In this post hoc analysis, primary outcomes include 30-day and 1-year mortality and morbidity and cumulative mortality and reinterventions. Cox regression analyses were performed to identify risk factors for mortality and reinterventions. RESULTS: Of the 521 patients (67% male; mean age, 67.2 ± 15 years), 329 were treated for thoracic aortic aneurysms, 56 for thoracic ulcers, 55 for acute and 31 for nonacute type B aortic dissections (TBADs), and 50 for blunt thoracic aortic injuries. The overall 30-day mortality rate was 1.7%, with perioperative stroke occurring in 3.1%, paraplegia in 1.2%, and proximal type I endoleak in 0.4% of patients within 30 days. At 1 year, the cumulative rate was 8.1% for all-cause mortality, 4.0% for stroke, 1.2% for paraplegia, 0.8% for proximal type I endoleak, and 6.0% for secondary interventions. Multivariate analysis showed that significant predictors for all-cause mortality included age (hazard ratio [HR], 1.04 for each additional year), congestive heart failure (HR, 2.87), serum creatinine (HR, 1.19 per 1 mg/dL), iliac tortuosity (HR, 1.32), blood transfusion (HR, 1.59 per 500 mL of packed red blood cells), and occurrence of 30-day stroke (HR, 3.93), paraplegia (HR, 7.79), or paraparesis (HR, 2.46). Patients treated for dissection, but not for thoracic aortic aneurysm or blunt thoracic aortic injury, demonstrated significantly higher risk for reintervention (HR, 5.65 for acute and 6.60 for nonacute TBADs) compared with patients treated for thoracic ulcers (reference group). Intraoperative contrast material (HR, 1.31 per 100 mL) and blood transfusion volumes (HR, 1.42 per 500 mL of packed red blood cells), surrogates of case complexity, were also significant predictors for reintervention. CONCLUSIONS: The results from the SUMMIT study demonstrated exceptionally low mortality and stroke rates at 30 days and low aortic disease-related mortality during follow-up. TBAD is associated with a higher risk for reintervention, possibly attributed to the natural history of the disease, whereas age, reduced cardiac and renal functions, difficult iliac access anatomy, intraoperative transfusion, and early neurologic complications are associated with higher risk for cumulative all-cause mortality.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Tsilimparis N, Debus S, Chen M, et al. Results from the Study to Assess Outcomes After Endovascular Repair for Multiple Thoracic Aortic Diseases (SUMMIT). J Vasc Surg. 2018. PMID: 29748101. doi:10.1016/j.jvs.2018.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。